Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Objective Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
- Trial name
- NCT05113693
- Testing
- CKD-393, CKD-501, D759, H053
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.
- Trial name
- FINEXPLORER (NCT07554469)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Bayer
Obesity and Overweight
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW).
- Trial name
- NCT06737042
- Testing
- GZR18, Tirzepatide
- Where
- 20 sites in United States
- Volunteers
- 326 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes Mellitus
Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study that will enroll approximately 564 T2DM patients who before screening have inadequately controlled blood glucose (7.0%≤HbA1c≤10.5% at…
- Trial name
- NCT02477969
- Testing
- PEX168(100µg), PEX168(200µg), Metformin
- Where
- China
- Volunteers
- 587 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of repaglinide plus metformin as initial treatment compared to repaglinide alone in Chinese subjects with type 2…
- Trial name
- NCT00819741
- Testing
- repaglinide, metformin
- Where
- 17 sites in China
- Volunteers
- 433 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-00915275 following administration to adult human subjects with T2DM for 4-weeks.
- Trial name
- NCT00427401
- Testing
- PF-00915275
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Sotagliflozin Bioequivalence Study
Primary Objective: To determine the bioequivalence of a single dose of the commercial tablet of sotagliflozin (test) compared to the development tablet of sotagliflozin (reference) under fasting conditions in healthy male and…
- Trial name
- NCT03211195
- Testing
- Sotagliflozin (SAR439954)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Dose-Range Finding Study for MK0893 (0893-008)
A study to compare MK0893 to metformin or placebo for patients with Type 2 diabetes (Diabetes Mellitus).
- Trial name
- NCT00479466
- Testing
- MK0893, Metformin
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
Primary objective: Efficacy assessment of the percentage of positive responders patients receiving Lantus plus glucophage association.
- Trial name
- GALATEE (NCT00653302)
- Testing
- Lantus (insulin glargine) + Glucophage (Metformin)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
This is an open-label, randomised study to compare the similarity of a combination Dapagliflozin/Metformin tablet with the two drugs administered separately under fasting and fed conditions in healthy volunteers.
- Trial name
- NCT01535677
- Testing
- Dapagliflozin + Glucophage tablet fasted, Dapagliflozin/metformin IR FDC tablet fasted, Dapagliflozin + Glucophage tablet fed
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 304 (NCT05504239)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2, Pre-diabetes
Prediabetes and Type 2 Diabetes Data Collection Study
To collect data in an observational study from Prediabetes (PD) and Type 2 Diabetes (T2D) patients including time correlated CGM, medication and food intake approximately 80% of the time for each subject that completes the entire…
- Trial name
- T2Help (NCT04503239)
- Testing
- G6
- Where
- 5 sites in United States
- Volunteers
- 306 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus Type 2
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
This 4 arm study will investigate the pharmacodynamics and pharmacokinetics of RO4998452 in type 2 diabetes patients with varying degrees of renal impairment.
- Trial name
- NCT00933972
- Testing
- RO4998452
- Where
- 2 sites in United States, Russia
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Diabetes
ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study
This double-blind, placebo-controlled, dose-finding study is designed to identify the lowest AGI-1067 dose that improves glycemic control as measured by HbA1c and fasting glucose in subjects with Type 2 diabetes mellitus.
- Trial name
- ANDES (NCT00525577)
- Testing
- AGI-1067
- Where
- 90 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 1,012 people
- Sponsor
- AtheroGenics
Diabetes Type 2
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.
- Trial name
- DURATION-NEO-2 (NCT01652729)
- Testing
- Exenatide once weekly suspension, Sitagliptin
- Where
- 60 sites in United States
- Volunteers
- 365 people
- Sponsor
- AstraZeneca
Diabetes
Experimental Study to Validate the Modified Glucose Disposal Test
Evaluate the modified GDT as a measure of key metabolic characteristics in healthy subjects and those with type 2 diabetes mellitus
- Trial name
- NCT01152372
- Testing
- Insulin, glucose and staple isotopes
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic…
- Trial name
- NCT02836574
- Testing
- Renal Autologous Cell Therapy (REACT), Renal Biopsy
- Where
- 16 sites in United States
- Volunteers
- 83 people
- Sponsor
- Prokidney
Hypertension
Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension
To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.
- Trial name
- NCT00060918
- Testing
- carvedilol, metoprolol
- Where
- 50 sites in United States
- Volunteers
- 1,210 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care
A multi-center, randomized, parallel, interventional, open label trial to compare Hemoglobin A1C-lowering effect of conventional treatment and Smart Care Service in patients with type 2 diabetes.
- Trial name
- Smart-DM (NCT01345435)
- Testing
- Telemonitoring group, Telemonitoring & Telemedicine, SMBG
- Where
- 4 sites in South Korea
- Volunteers
- 417 people
- Sponsor
- CHANGHEE LEE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.